Anti-TMIGD3 antibodies are used in the immunodetection of the protein transmembrane and immunoglobulin domain containing 3. In humans, the canonical protein has a reported length of 266 amino acid residues and a mass of 30.3 kDa. Its subcellular localization is in the membrane. Up to 3 different isoforms have been reported for this protein. It is reported to be expressed in the lung and bone. TMIGD3 is known to play a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity. Post-translational modifications have been described, including glycosylation. Synonyms for this target antigen include AD026 protein (AD026) and transmembrane domain-containing protein TMIGD3. TMIGD3 gene orthologs have been reported in the mouse, rat, bovine and chimpanzee species.